Caplin Point trades jubilantly on getting Brazil's ANVISA approval for sterile injectable site

03 Sep 2015 Evaluate

Caplin Point Laboratories is currently trading at Rs. 1540.00, up by 147.00 points or 10.55% from its previous closing of Rs. 1393.00 on the BSE.

The scrip opened at Rs. 1411.00 and has touched a high and low of Rs. 1549.75 and Rs. 1399.00 respectively. So far 24703 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1549.75 on 3-Sept-2015 and a 52 week low of Rs. 337.00 on 21-Oct-2014.

Last one week high and low of the scrip stood at Rs. 1549.75 and Rs. 1271.00 respectively. The current market cap of the company is Rs. 2115.40 crore.

The promoters holding in the company stood at 67.81% while Institutions and Non-Institutions held 1.82% and 30.37% respectively.

Caplin Point Laboratories has received approval from Brazil's National Health Surveillance Agency ANVISA (Agencia Nacional de Vigilancia Sanitaria) for its sterile injectable manufacturing site at Chennai. The facility is capable of manufacturing Liquid Injectables in Vials, Ampoules, Lyophilized Vials and Ophthalmic dosages.

The approval grants access to the company to register and market its products at the large and growing Brazilian Pharmaceutical market.

Caplin Point Laboratories is a niche pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa.

Caplin Point Lab Share Price

1964.95 -5.95 (-0.30%)
17-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1751.05
Dr. Reddys Lab 1163.70
Cipla 1515.45
Lupin 1936.75
Zydus Lifesciences 831.40
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...